Gastric
HLX22-GC-301
A Randomized, Double-blinded, Multicentre, Phase III Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy (XELOX) versus Trastuzumab and Chemotherapy (XELOX) with or without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer
Trial overview
Clinical Area
Medical Oncology
Disease
Gastric
Disease site
Gastroinstestinal
Study Phase
III
Trial Identifiers
Registration number: NCT06532006
GenesisCare Location(s)
Principal Investigator(s)
Clinical trials enquiries